• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Steady-state kinetics and dosage requirements of cimetidine in renal failure.

作者信息

Larsson R, Norlander B, Bodemar G, Walan A

出版信息

Clin Pharmacokinet. 1981 Jul-Aug;6(4):316-25. doi: 10.2165/00003088-198106040-00006.

DOI:10.2165/00003088-198106040-00006
PMID:7249490
Abstract

25 patients with different degrees of chronic stable renal failure received oral treatment with cimetidine over 6 days and a final dose in the morning of day 7. The doses of cimetidine were reduced according to the degree of renal failure. Plasma concentrations of cimetidine were determined before the morning dose on days 2,3,6 and before the final morning dose and during the day on day 7. 24-hour excretions of cimetidine were measured during the study and on day 7, 6 to 9 hours after the final morning dose. There were significant linear relationships between the values of creatinine clearance and plasma elimination rate constant of cimetidine (p less than 0.0025) and between the values of creatinine clearance and renal clearance of cimetidine (p less than 0.05). On the basis of the morning plasma concentrations before and the plasma concentration curve after the final morning dose on day 7 the following dose recommendations according to pretrial values of creatinine clearance are recommended for cimetidine treatment in renal failure: 5 to 15ml/min 200mg 2 or 3 times daily, 15 to 30ml/min 200mg 3 times daily and 30 to 75ml/min 200mg 4 times daily.

摘要

相似文献

1
Steady-state kinetics and dosage requirements of cimetidine in renal failure.
Clin Pharmacokinet. 1981 Jul-Aug;6(4):316-25. doi: 10.2165/00003088-198106040-00006.
2
The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.西咪替丁及其亚砜代谢产物在肾功能正常和受损患者中的药代动力学。
Br J Clin Pharmacol. 1982 Feb;13(2):163-70. doi: 10.1111/j.1365-2125.1982.tb01351.x.
3
Oral absorption of cimetidine and its clearance in patients with renal failure.
Eur J Clin Pharmacol. 1979 Apr 17;15(3):153-7. doi: 10.1007/BF00563098.
4
Elimination of oral cimetidine in chronic renal failure and during haemodialysis.慢性肾功能衰竭及血液透析期间口服西咪替丁的消除情况。
Br J Clin Pharmacol. 1980 Jun;9(6):585-92. doi: 10.1111/j.1365-2125.1980.tb01084.x.
5
Pharmacokinetics of cimetidine after single doses and during continuous treatment.西咪替丁单次给药及持续治疗期间的药代动力学。
Clin Pharmacokinet. 1981 Jul-Aug;6(4):306-15. doi: 10.2165/00003088-198106040-00005.
6
Pharmacokinetics of cimetidine in patients undergoing hemodialysis.
Nephron. 1983;34(3):159-63. doi: 10.1159/000183002.
7
Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.西咪替丁及其亚砜代谢物在血液透析期间的药代动力学。
Eur J Clin Pharmacol. 1982;21(4):325-30. doi: 10.1007/BF00637621.
8
Cimetidine clearance during intermittent and chronic peritoneal dialysis.间歇性和慢性腹膜透析期间西咪替丁的清除率
Am J Hosp Pharm. 1981 Nov;38(11):1760-2.
9
The effects of cimetidine (Tagamet) on renal function in patients with renal failure.西咪替丁(泰胃美)对肾衰竭患者肾功能的影响。
Acta Med Scand. 1980;208(1-2):27-31. doi: 10.1111/j.0954-6820.1980.tb01145.x.
10
Altered disposition and availability of cimetidine in liver cirrhotic patients.肝硬化患者中西咪替丁的处置和可用性改变。
Br J Clin Pharmacol. 1982 Sep;14(3):421-30. doi: 10.1111/j.1365-2125.1982.tb02002.x.

引用本文的文献

1
Risk Factors for Upper Gastrointestinal Bleeding in Patients Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy with Assessment of Anti-Ulcer Medication Effects.接受经皮冠状动脉介入治疗并接受双重抗血小板治疗的患者发生上消化道出血的危险因素及抗溃疡药物疗效评估
Acta Cardiol Sin. 2025 Mar;41(2):183-191. doi: 10.6515/ACS.202503_41(2).20240722A.
2
Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population.慢性肾脏病人群中肌氨酸酐-药物相互作用的基于生理学的药代动力学模型。
CPT Pharmacometrics Syst Pharmacol. 2020 Dec;9(12):695-706. doi: 10.1002/psp4.12566. Epub 2020 Nov 23.
3

本文引用的文献

1
Pharmacokinetics of cimetidine after single doses and during continuous treatment.西咪替丁单次给药及持续治疗期间的药代动力学。
Clin Pharmacokinet. 1981 Jul-Aug;6(4):306-15. doi: 10.2165/00003088-198106040-00005.
2
The effects of cimetidine (Tagamet) on renal function in patients with renal failure.西咪替丁(泰胃美)对肾衰竭患者肾功能的影响。
Acta Med Scand. 1980;208(1-2):27-31. doi: 10.1111/j.0954-6820.1980.tb01145.x.
3
Functional defects in the aging kidney.衰老肾脏中的功能缺陷。
Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.
肾功能不全患者中H2受体拮抗剂的药代动力学和药效学
Clin Pharmacokinet. 1993 Apr;24(4):319-32. doi: 10.2165/00003088-199324040-00005.
4
Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.肾衰竭患者消化性溃疡治疗的药代动力学优化
Clin Pharmacokinet. 1994 Nov;27(5):393-408. doi: 10.2165/00003088-199427050-00006.
5
Pharmacokinetics of cimetidine after single doses and during continuous treatment.西咪替丁单次给药及持续治疗期间的药代动力学。
Clin Pharmacokinet. 1981 Jul-Aug;6(4):306-15. doi: 10.2165/00003088-198106040-00005.
6
Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.西咪替丁及其亚砜代谢物在血液透析期间的药代动力学。
Eur J Clin Pharmacol. 1982;21(4):325-30. doi: 10.1007/BF00637621.
7
Clinical pharmacokinetics of cimetidine.西咪替丁的临床药代动力学
Clin Pharmacokinet. 1983 Nov-Dec;8(6):463-95. doi: 10.2165/00003088-198308060-00001.
8
Dosage regimen of cimetidine reviewed. Possible drug accumulation after multiple oral doses.西咪替丁给药方案综述。多次口服给药后可能的药物蓄积。
Eur J Clin Pharmacol. 1988;34(6):539-42. doi: 10.1007/BF00615214.
9
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).用于治疗胃肠道疾病的药物的临床药代动力学(第二部分)。
Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002.
10
Prediction of the renal clearance of cimetidine using endogenous N-1-methylnicotinamide.
J Pharmacokinet Biopharm. 1991 Apr;19(2):175-88. doi: 10.1007/BF01073868.
Ann Intern Med. 1972 Jan;76(1):41-5. doi: 10.7326/0003-4819-76-1-41.
4
Rapid evaluation of creatinine clearance.
Acta Med Scand. 1974 Dec;196(6):517-20. doi: 10.1111/j.0954-6820.1974.tb01053.x.
5
The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease.西咪替丁维持治疗前后的吸收情况以及进餐对西咪替丁吸收的影响——对消化性溃疡病患者的研究
Br J Clin Pharmacol. 1979 Jan;7(1):23-31. doi: 10.1111/j.1365-2125.1979.tb00892.x.
6
Cimetidine and mental confusion.
Am J Hosp Pharm. 1978 Sep;35(9):1035.
7
Cimetidine and mental confusion.
JAMA. 1978 Jun 16;239(24):2550-1. doi: 10.1001/jama.1978.03280510034011.
8
Effects of renal failure on blood levels of cimetidine.
Gastroenterology. 1978 Feb;74(2 Pt 2):473-7.
9
Bioavailability of cimetidine in man.西咪替丁在人体中的生物利用度。
Gastroenterology. 1978 Feb;74(2 Pt 2):360-5.
10
Cimetidine and mental confusion.西咪替丁与精神错乱
N Engl J Med. 1978 Feb 2;298(5):284-5.